AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00787072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8075
Description: Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.
Study NCT00787072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study NCT00079339 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT01982799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral acetaminophen/hydrocodone + ibuprofen
Description: vicodin/ibuprofen
Study NCT00079339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT02349945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: follitropin alpha
Description: All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.~Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage > 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle.
Study NCT04181112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: FMT using retention enema
Study NCT04312256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TetraGraph
Description: FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin (ECG) electrodes.
Study NCT00940875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg po on days 15-28 of each 4 week cycle
Study NCT00940875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250mg/m2/day on days 1 and 8 of each 4 week cycle
Study NCT00940875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000mg/m2/day on days 1, 8 and 15 of each 4 week cycle
Study NCT02884037 — intervention group
Intervention type: DRUG
Intervention: Rifaximin group 1
Description: Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals
Study NCT02547272 — intervention group
Intervention type: PROCEDURE
Intervention: Nasal and rectal bacterial samples
Description: Bacterial nasal and rectal samples at admission and one weekly for the presence of S Aureus
Study NCT01943682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Comparison of Different doses of drug
Study NCT05096039 — intervention group
Intervention type: DRUG
Intervention: Sacubitril/valsartan
Description: Beneficiaries with one or more prescription claim with an NDC for sacubitril/valsartan (from the PDE file) during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
Study NCT05096039 — intervention group
Intervention type: DRUG
Intervention: ACEI or ARB and no sacubitril/valsartan
Description: Beneficiaries with one or more prescription claim with an NDC for any ACEI/ARB and no prescription claims for sacubitril/valsartan during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
Study NCT01189110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy using TENS unit Stim Flex 400A
Description: Although the mechanism of action of auriculotherapy is not well understood, the dominant scientific theory for how traditional acupuncture procedures works has suggested possible neurophysiologic and neurochemical pathways that may explain its effectiveness for treating specific disorders
Study NCT01189110 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Auriculotherapy using TENS unit Stim Flex 400A
Description: Although the mechanism of action of auriculotherapy is not well understood, the dominant scientific theory for how traditional acupuncture procedures works has suggested possible neurophysiologic and neurochemical pathways that may explain its effectiveness for treating specific disorders
Study NCT02420249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong training
Description: Participants will learn the 18 Forms of Tai Chi Internal Qigong. Detailed movement and breathing descriptions of the Qigong training protocol can been found in Mak YK. 18 Forms Tai Chi Qigong \[in Chinese\]. 7th ed. Hong Kong: Wan Li Book Co.; 2012.
Study NCT01210326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extaction
Description: TESE (testicular sperm extraction), which is actually a surgical biopsy of the testis; or TESA (testicular sperm aspiration), which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure
Study NCT01210326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: testicular sperm extraction
Description: testicular sperm extraction
Study NCT01210326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: testicular sperm aspiration
Description: testicular sperm aspiration
Study NCT01038453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol 35 µg per day
Description: Cholecalciferol (Vitamin D3) oral 1 tablet 35 µg per day. Placebo oral 1 tablet per day. In total 35 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery.
Study NCT01038453 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: placebo 2 tablet, once a day,
Study NCT01038453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (Vitamin D3) 70 µg
Description: Cholecalciferol (Vitamin D3) oral 2 tablets each containing 35 µg. In total 70 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery.
Study NCT04832295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: photo-supported conversations
Description: Sessions 1-4: Before each of the sessions, the client photographs that which is related to their well-being and send these to the therapist before the session. The therapist enlarges each of the photographs into the size of A4. The conversation departures from the photographs and the client is encouraged to talk about each of them and they ways it relates to their well-being. Potential strategies for everyday life are discussed.~Session 5-10: short virtual meetings of approximately 15-20 minutes with the aim to follow the client, confirm their process and support them towards increased well-being.~Session 11: reflecting upon all their previous photographs. Session 12: reflecting future everyday life upon their photographs.
Study NCT04832295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: Medication, psychological treatment
Study NCT04832295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care as usual
Description: Medication, psychological treatment
Study NCT01349452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Ganciclovir 0.15% Ophthalmic gel
Study NCT01349452 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Artificial tear
Description: Artificial tear 5 times per day
Study NCT05775783 — intervention group
Intervention type: PROCEDURE
Intervention: Transvenous lead extraction
Description: Each TLE procedure was started using the single traction method. If this attempt was not sufficient to extract the lead, then the following methods were used: mechanical extraction sheaths (Byrd, Cook Vascular Inc., Leechburg, PA, USA), locking and nonlocking stylets (Liberator® Beacon® Tip Locking Stylet, Cook® Medical, Leechburg, PA, USA), powered extraction sheaths (Evolution or Evolution II Mechanical Dilator Sheath, Cook® Medical, Leechburg, PA, USA). A side retrieval snare loop (Needle's Eye Snare, Cook® Medical, Leechburg, PA, USA) was used for the femoral approach when the subclavian-only approach was insufficient.
Study NCT02768883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respira Sano
Description: The intervention is all three components: clinic + home + community.
Study NCT02768883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respira Sano
Description: The intervention is all three components: clinic + home + community.
Study NCT01516749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra
Description: Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.
Study NCT04197167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: Diagnostic procedure
Study NCT04197167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared Spectroscopy
Description: This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of Chronic Endometritis
Study NCT02729467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: JNJ-53718678 will be applied twice at doses of 250 mg (in Panel 1, Day 1 and Day 9) and 3 times at 500 mg (Panel 2, Day 1, 4 and 9).
Study NCT02729467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive itraconazole 200 mg (2 capsules of 100 mg) from Day 4-11.
Study NCT02729467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Participants will receive 600 mg rifampicin (2 capsules of 300 mg) from Day 4-11.
Study NCT03782571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon a Test 1
Description: 1-DAY ACUVUE® MOIST
Study NCT03782571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Test 2
Description: 1-DAY ACUVUE® MOIST for ASTIGMATISM
Study NCT02480647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: 20μg/day.
Study NCT02480647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel
Description: 20μg/day.
Study NCT04577131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly check-in
Description: Weekly check-in phone calls from a pharmacist to review blood pressures and the number of times tested in that week
Study NCT03735043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiac output by ccNexfin ©
Description: Measurement of cardiac output by ccNexfin © comparatively to transthoracic echocardiography Subjects participating to the study will be simultaneously measured for cardiac output by ccNexfin © and transthoracic echocardiography. Echocardiographic measurements of cardiac output will be blinded to values measured by ccNexfin ©. For each participant, a first measurement of cardiac output will be performed in the supine position and then after 1 minute of strict left lateral position.
Study NCT02964702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombectomy Device T-01
Study NCT02454504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Study NCT02454504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Study NCT01199978 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Fractionated proton radiation
Description: Given daily for approximately 5.5 weeks
Study NCT01199978 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Losartan
Description: 25mg or 50mg daily, oral administration, for approximately 6 months.
Study NCT01418404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noxious TS
Description: hot, cold alternately, noxious TS in study A
Study NCT01418404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Innocuous TS
Description: warm, cool alternately, Innocuious TS in study A
Study NCT01418404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Frequency of Noxious TS
Description: High Frequency of Noxious TS in study B
Study NCT01418404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Frequency of Noxious TS
Description: Low Frequency of Noxious TS in study B
Study NCT01418404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity of Noxious TS
Description: High Intensity of Noxious TS in study C
Study NCT01418404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity of Noxious TS
Description: Low Intensity of Noxious TS in study C
Study NCT03054337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Study NCT03054337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03396068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-101
Description: NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
Study NCT03396068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone HCl
Description: Lurasidone HCl will be given twice a day by mouth
Study NCT02274090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel consist of drug without the active component.
Study NCT02274090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Metformin gel
Description: Metformin gel consist of active component.
Study NCT01327612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: The mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m² administered as a 2-hour intravenous (IV) infusion on day 1 and leucovorin 400 mg/m² racemate or 200 mg/m² levo-leucovorin administered as a 2-hour infusion on day 1, followed by a loading dose of 5-fluorouracil (5-FU) 400 mg/m² IV bolus administered on day 1, then 5-FU 2400 mg/m² via ambulatory pump administered for a period of 46 to 48 hours every 14 days.
Study NCT01327612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conatumumab
Description: Administered by intravenous infusion Q2W or Q3W.
Study NCT01327612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: Administered by intravenous infusion Q3W or Q4W.
Study NCT01327612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle.
Study NCT01070576 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT01908751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sliding Hip Screw
Study NCT01908751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cancellous Screws
Study NCT01908751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT01908751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D Placebo
Study NCT03908892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanthoxylum nitidum tincture
Description: Local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day.
Study NCT03908892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetracycline ointment
Description: Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day
Study NCT03908892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracycline ointment
Description: Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day
Study NCT01821105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: All patients will receive whole body PET scans (chest-abdomen-pelvis).
Study NCT01821105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: All patients will receive CT scans of the abdomen and pelvis with contrast.
Study NCT01821105 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Given IV
Study NCT01821105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer-aided detection/diagnosis
Description: Undergo computer-aided detection/diagnosis during surgery
Study NCT04688177 — intervention group
Intervention type: DEVICE
Intervention: Body Composition
Description: The subjects should lie in the supine position on a non-conducting surface for 5 min. 4 surface electrodes with cables will be attached to the right hand and ankle of subjects.
Study NCT04688177 — intervention group
Intervention type: DEVICE
Intervention: Heart rate variability
Description: After supine quietly for 20 min, a lead I electrocardiogram will be taken for 5 min.
Study NCT04688177 — intervention group
Intervention type: DEVICE
Intervention: Grip Strength
Description: The participants will squeeze the hand dynamometer as hard as possible with the dominant hand. 3 successive measurements will be taken.
Study NCT04688177 — intervention group
Intervention type: DEVICE
Intervention: Exhale Carbon Monoxide Concentration
Description: Subjects in sitting position, performing 1 inspiration, then exhale to carbon monoxide meter.
Study NCT04688177 — intervention group
Intervention type: DEVICE
Intervention: Pulmonary Function Test
Description: Subjects should be in a sitting position with a nose clip, then perform pulmonary function test. Participants should perform at least 3 acceptable attempts, but no more than 8 attempts in total.
Study NCT04688177 — intervention group
Intervention type: DEVICE
Intervention: Respiratory Muscle Function
Description: Subject will perform both maximal inspiratory pressure and maximal expiratory pressure for 3 times in sitting position with the nose clip.
Study NCT04688177 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fagerström Test for Nicotine Dependence
Description: Fagerström Test for Nicotine Dependence Traditional Chinese version will be adopted. It is a 6-item questionnaire that could help quantify the smoking frequency, amounts, and level of dependence.
Study NCT04688177 — intervention group
Intervention type: BEHAVIORAL
Intervention: Seven-Day Physical Activity Recall Questionnaire
Description: Physical activity will be measured by the Chinese Version of the Seven-Day Physical Activity Recall Questionnaire. Participants will need to recall the time (hours) they spent in various leisure activities in the past 7 days.
Study NCT04688177 — intervention group
Intervention type: DEVICE
Intervention: Cardiopulmonary exercise testing
Description: Bruce protocol as the treadmill evaluation protocol will be adopted for cardiopulmonary exercise testing.
Study NCT00202189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Nebulized Budesonide (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered to subjects once only.
Study NCT00202189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide
Description: Nebulized Budesonide (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered to subjects once only.
Study NCT00775411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 700 µg dexamethasone intravitreal injection at Day 1 in the study eye.
Study NCT00775411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
Study NCT02361086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally once daily in 28 day cycles
Description: VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.
Study NCT01111253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Amoxicillin-clavulanate: 4 times a day 1200 mg and switch to oral administration 3 times a day 625 mg after two days, for a total duration of 10 days.~In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral administration ciprofloxacin 2 times a day 500 mg and metronidazole 3 times a day 500 mg. For a total duration of 10 days.
Study NCT04652388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Nutritional counseling about mediterranean diet
Study NCT00663585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vipassana Meditation
Description: 12 day retreat where participants learn to meditate
Study NCT00663585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vipassana Meditation
Description: 12 day retreat where participants learn to meditate
Study NCT03306173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Commercially available cigarette
Description: Commercially available cigarette with either \~0% or \~25% filter ventilation. Menthol flavor will be available in both types.
Study NCT01702857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant
Study NCT01702857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant
Study NCT01702857 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate buffered saline
Study NCT01702857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 µg TDENV-PIV with Alum adjuvant